Mubadala & Resilience partner to develop biopharma manufacturing in UAE

By Shilpa Annie Joseph, Official Reporter
  • Follow author on
Mubadala-Resilience Partnership
Officials during the signing ceremony.

Abu Dhabi sovereign investor, Mubadala Investment Company has signed an agreement with US-based National Resilience (Resilience) in order to establish a new biopharma manufacturing facility in the UAE.

Resilience is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.

Under the agreement, Mubadala will establish the new manufacturing facility, which will be operated by Resilience, to manufacture certain biopharmaceutical-related products in the UAE.

The facility will include a range of therapeutics for complex diseases such as cancer, infectious diseases, and inflammatory and autoimmune disorders, as well as vaccines.

As part of the collaboration, Resilience has agreed to provide manufacturing, technology, and operational expertise for the Abu Dhabi-based facility and integrate the site as a node within its global network.

Commenting on the agreement, Badr Al-Olama Executive Director, UAE Investment Platform at Mubadala, stated that, “Through this agreement, Mubadala and its group companies will unlock further opportunities for growth within the life sciences ecosystem, and alongside our key partners, will play an instrumental role in establishing a state-of-the-art biopharma campus that will secure the region’s supply chain from Abu Dhabi.”

Furthermore, the Abu Dhabi-based facility will be the first Goods Manufacturing Practice (GMP) biopharma facility in the UAE as well as the first of its kind in the region to manufacture essential life sciences products for advanced biologics.

“We are excited to expand the footprint of our Resilience manufacturing network outside of North America. This is a significant milestone, not just for our company but also for our nation. We look forward to working alongside America’s allies in the region to ensure that trusted, cutting-edge biopharmaceutical manufacturing capacity is available to support local, regional and global economies,” said Mr. Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.

Related: Bahrain’s Al Baraka Bank pens medical finance deal with KIMSHealth & RBH